Document is current
Any future updates will be listed below
-
Authors
Gadiyar, Varsha
Pulica, Rachael
Aquib, Ahmed
Tranos, James A. https://orcid.org/0000-0002-3521-029X
Varsanyi, Christopher https://orcid.org/0009-0000-8416-5141
Frederick, Trevor https://orcid.org/0009-0009-3137-3794
Wang, Ziren
Almansa, Luis Fernandez
Gaspers, Lawrence
De Lorenzo, Mariana S.
Kotenko, Sergei V.
Tripathi, Sushil
Howell, Roger W.
Choudhary, Alok
Calianese, David C.
Birge, Raymond B. https://orcid.org/0009-0004-0104-8978
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA260137-04)
- License Information
-
More Information
Article History
Received: 7 May 2025
Revised: 2 September 2025
Accepted: 23 September 2025
First Online: 6 November 2025
Competing interests
: SVK and RBB are cofounders of a biotechnology company called Targeron Therapeutics, LLC, that aims to develop PS-targeting IFNs for immune-oncology applications.
